China Biopharmaceutical (01177): TQB2102 Injection "HER2 Bispecific Epitope Bispecific Antibody-Drug Conjugate (ADC)" New Drug Application Accepted

Zhito Finance APP News, China Biopharmaceutical (01177) announced that the National Class 1 innovative drug TQB2102 injection "HER2 bispecific epitope bispecific antibody ADC," independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has submitted a New Drug Application to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration and has been accepted, for the treatment of adult patients with unresectable or metastatic HER2-low expression (IHC 1+ or IHC 2+/ISH-) breast cancer who have not previously received chemotherapy in the recurrent or metastatic disease setting. Previously, this indication was included by the CDE in the breakthrough therapy category.